

Dynamic regulation of innate immune responses in *Drosophila* by Senju-mediated glycosylation

Miki Yamamoto-Hino^a, Masatoshi Muraoka^b, Shu Kondo^c, Ryu Ueda^c, Hideyuki Okano^d, and Satoshi Goto^{a,d,1}

^aDepartment of Life Science, Rikkyo University, Tokyo 171-8501, Japan; ^bStem Cell Project Group, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan; ^cInvertebrate Genetics Laboratory, Genetic Strains Research Center, National Institute of Genetics, Mishima 411-8540, Japan; and ^dDepartment of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan

Edited by Norbert Perrimon, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, and approved March 30, 2015 (received for review December 22, 2014)

The innate immune system is the first line of defense encountered by invading pathogens. Delayed and/or inadequate innate immune responses can result in failure to combat pathogens, whereas excessive and/or inappropriate responses cause runaway inflammation. Therefore, immune responses are tightly regulated from initiation to resolution and are repressed during the steady state. It is well known that glycans presented on pathogens play important roles in pathogen recognition and the interactions between host molecules and microbes; however, the function of glycans of host organisms in innate immune responses is less well known. Here, we show that innate immune quiescence and strength of the immune response are controlled by host glycosylation involving a novel UDP-galactose transporter called Senju. In *senju* mutants, reduced expression of galactose-containing glycans resulted in hyperactivation of the Toll signaling pathway in the absence of immune challenges. Genetic epistasis and biochemical analyses revealed that Senju regulates the Toll signaling pathway at a step that converts Toll ligand Spatzle to its active form. Interestingly, Toll activation in immune-challenged wild type (WT) flies reduced the expression of galactose-containing glycans. Suppression of the degalactosylation by *senju* overexpression resulted in reduced induction of Toll-dependent expression of an antimicrobial peptide, Drosomycin, and increased susceptibility to infection with Gram-positive bacteria. These data suggest that Senju-mediated galactosylation suppresses undesirable Toll signaling activation during the steady state; however, Toll activation in response to infection leads to degalactosylation, which raises the immune response to an adequate level and contributes to the prompt elimination of pathogens.

innate immunity | glycosylation | Toll pathway | nucleotide sugar transporter | galactose

The innate immune system is the first line of defense against invading pathogens. In the steady state, immune responses are restrained; however, the immune response is activated rapidly on pathogen recognition. The Toll/TLR (Toll-like receptor) pathway plays a conserved role in the innate immune system of insects and vertebrates (1–3). In *Drosophila*, pathogens are not directly recognized by the Toll transmembrane receptor; rather, they are recognized by several specific pattern recognition receptors. The binding of gram-positive bacteria and fungi by these pattern recognition receptors triggers the activation of the serine protease cascade. Finally, a precursor form of Spatzle (pro-Spz), an endogenous ligand for Toll, is converted to an active form, which binds Toll and triggers activation of the NF- κ B–related transcription factor, Dorsal-related immunity factor (Dif), leading to transcription of genes encoding antimicrobial peptides (AMPs) including Drosomycin (Drs). Many of the extracellular components required for Toll activation and suppression have been identified and are well understood; however, it is less known whether the posttranslational modifications in host organisms, such as glycosylation, regulate innate immune responses, despite the known significant roles of glycosylation in various other biological processes (4, 5).

Most cell surface and secreted proteins are glycosylated in the endoplasmic reticulum (ER) and Golgi apparatus. Glycosylation requires glycosyltransferases and nucleotide sugar substrates that are synthesized in the cytosol and nucleus. The nucleotide sugars must be transported into the ER and Golgi lumens by nucleotide sugar transporters (NSTs) (6). On arrival, they are used by glycosyltransferases. The *Drosophila* genome encodes at least 10 NSTs, which transport different subsets of nucleotide sugars. Studies of mutated NST genes show that protein glycosylation regulates intercellular signaling events. For example, Fringe-connection (a UDP-sugar transporter) (7, 8) and the two GDP-fucose transporters Gfr (9) and Efr (10) all affect Notch glycosylation and activity. *Drosophila* Gfr has a mammalian ortholog called SLC35C, which is responsible for the congenital disorder of glycosylation IIc (11, 12). These reports suggest that mutant NSTs in *Drosophila* may be useful tools for investigating the roles of glycosylation in regulation of signaling and in human diseases.

Here, we report that flies harboring a mutation of a novel UDP-galactose transporter named Senju showed hyperactivation of immune signal transduction via the Toll, JAK/STAT, and JNK signaling pathways in the absence of immune challenge. We focused on identifying the mechanism underlying Toll pathway activation and found that Spz was activated in the *senju* mutant. Moreover, we found that activation of the Toll pathway reduced the amount of galactose-containing glycan. Accordingly, *senju* overexpression increased galactose-containing glycan levels and repressed activation of the immune response against pathogens. These results suggest that the immune response is dynamically regulated by the amount of galactose-containing

Significance

The innate immune system is the first line of defense against invading pathogens. Activation of the innate immune response by infection and suppression during steady state are stringently controlled to eliminate pathogens and prevent inflammation. We found that host glycosylation plays an important role in the activation of immune responses and in maintaining innate immune homeostasis. In the steady state, a high amount of galactose-containing glycan suppresses undesirable activation of the immune response; however, activation of immune responses leads to reduced levels of galactose-containing glycan, which is needed for raising immune responses to an adequate level. Our finding suggests a novel mechanism for the regulation of innate immune quiescence and activation via changes in glycosylation status.

Author contributions: M.Y.-H. and S.G. designed research; M.Y.-H. and S.K. performed research; M.Y.-H., M.M., S.K., R.U., and H.O. contributed new reagents/analytic tools; M.Y.-H. and S.G. analyzed data; and M.Y.-H. and S.G. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

¹To whom correspondence should be addressed. Email: stgoto@rikkyo.ac.jp.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1424514112/-DCSupplemental.

glycan, which is high during steady state to maintain immune homeostasis and low in infection to favor prompt elimination of pathogens.

Results

Senju KO Flies Have Abnormal Immune Organs. To analyze the biological role of *Drosophila* NSTs, we generated a series of knock out (KO) flies by homologous recombination (*SI Materials and Methods* and Fig. S1). Of these, CG14040 KO flies, which are called *senju*¹ in the present study, showed various abnormalities in their immune organs. These abnormalities included melanotic cells in the hemocoel and melanotic tumors in the lymph glands, which are a specialized larval hematopoietic organ in *Drosophila* (Fig. 1 A–C). The lymph glands were also enlarged (Fig. 1 B, E, G, and I). Therefore, we investigated whether normal hematopoiesis occurs in *senju*¹. Normally, at the late third-instar larval stage, progenitor hemocytes mature into plasmatocytes, crystal cells, and lamellocytes in the lymph gland (13); thus, lymph glands from WT and *senju*¹ larvae were stained with anti-Nimrod C (a marker of plasmatocytes) (14) and anti-L1 (a marker of lamellocytes) (15) antibodies. In immunologically unchallenged WT larvae, most of the differentiated hemocytes were plasmatocytes, which were located along the outer edge of the lymph gland (Fig. 1D). Progenitor cells, which were located within the inner core of the lymph gland, were identified by their expression of *domeless* (*dome*) (Fig. 1F) (16), which encodes a receptor that functions in the JAK/STAT signaling pathway. Because lamellocytes are only induced by immune challenge, no lamellocyte staining was observed in the WT larvae (Fig. 1H) (13). By contrast, in immunologically unchallenged *senju*¹ larvae, the numbers of progenitor cells and plasmatocytes were reduced, and we noted a significant degree of differentiation into lamellocytes in the primary and secondary lobes (Fig. 1 E, G, and I). Constitutive melanization and hyperdifferentiation of lamellocytes

were also observed in *Toll* gain-of-function (*Tl*^{10B}) (17) and JAK gain-of-function (*hop*^{tm¹}) (18, 19) mutants of *Drosophila*. Therefore, we next investigated whether the Toll and JAK/STAT signaling pathways were activated in *senju*¹. Because homozygous *senju*¹ died at the late larval or early pupal stages, the majority of experiments (except for some that used adult flies) were performed using late-stage larvae.

Signaling Pathways Involved in Innate Immunity Are Activated in *senju*¹ in the Absence of Immune Challenge. The Toll signaling pathway is the most important pathway in innate immunity against gram-positive bacteria and fungi (2, 20). We found that the Toll pathway was activated in *senju*¹ by quantifying the expression of *Drs*. In the absence of immune challenge, *senju*¹ larvae expressed ~50-fold higher *Drs* mRNA levels than unchallenged WT larvae. The *Drs* mRNA levels in *senju*¹ were 50% of the *Drs* mRNA levels of control larvae collected 12 h after infection with *Micrococcus luteus* (*M. luteus*), a gram-positive bacterium (Fig. 2A). The up-regulation of *Drs* in *senju*¹ was significantly reduced by the over-expression of Myc-tagged *senju* using *sp-Gal4* (Fig. 2A), confirming that *senju* was the gene responsible for the constitutive up-regulation of *Drs* mRNA levels in *senju*¹. We also observed *Drs* induction in *senju*¹ larvae cultured under germ-free conditions (Fig. S2), indicating that up-regulation of *Drs* mRNA in *senju*¹ is likely to be due to host factors rather than commensal bacteria.

We then tested whether this constitutive expression of *Drs* in *senju*¹ depended on *dorsal* (*dl*) and *Dif*, the NF- κ B-related transcription factors in the Toll pathway. Indeed, a *dl* and *Dif* double mutation (*J4*) suppressed the induction of *Drs* mRNA in *senju*¹ (Fig. 2A), supporting the notion that the Toll pathway is activated in *senju*¹. Taken together, the Toll signaling pathway is most likely to be negatively regulated by Senju.

JAK/STAT signaling also plays a crucial role in regulating immune responses in *Drosophila* (21). Thioester-containing protein 1 (*Tep1*) is one gene regulated by the JAK/STAT pathway (22). Therefore, we quantified the expression of *Tep1* mRNA. Unchallenged *senju*¹ expressed 44-fold higher levels of *Tep1* mRNA than unchallenged control larvae (Fig. 2B). The *Tep1* mRNA levels in *senju*¹ were even higher than the *Tep1* mRNA levels in control larvae collected 12 h after infection with *M. luteus* (Fig. 2B). We also examined the activation of JAK/STAT signaling by using GFP reporter flies that harbor a *GFP* gene downstream of two STAT-binding sequences (2 \times STAT-GFP; Fig. 2C) (23). The larvae of 2 \times STAT-GFP-bearing *senju*¹ showed constitutive activation of the JAK/STAT pathway.

Previous studies showed that the JNK signaling pathway also contributes to immune responses in insects and mammals. Activation of the JNK signaling pathway is induced by pathogens (24, 25) and is required for the expression of AMPs (26). Therefore, we examined whether the JNK signaling pathway is also activated in *senju*¹ by measuring the levels of *puckered* (*puc*) mRNA, which are increased by JNK pathway activation (27). Unchallenged *senju*¹ had a 6.6-fold higher *puc* transcription compared with the unchallenged control larvae (Fig. 2D). The *puc* transcription was also higher than that observed in challenged control larvae.

We next used *Drs*-GFP (a readout for the Toll pathway), 10 \times STAT-GFP (a readout for the JAK/STAT pathway), and *puc*-lacZ (a readout for the JNK pathway) to examine which tissues are involved in activating these signals in *senju*¹. As shown in Fig. S3, a strong *Drs*-GFP signal was observed in the fat body but not in the lymph gland. By contrast, the JAK/STAT and JNK pathways were activated in the lymph gland rather than in the fat body.

The Imd pathway is another NF- κ B-dependent signaling pathway that is involved in innate immunity (28). We tested whether the Imd signaling pathway was affected in *senju*¹ by measuring the expression of *Diptericin* (*Dpt*), which is a major target gene of the Imd pathway. *senju*¹ expressed similar, or lower, *Dpt* mRNA levels




Fig. 1. Loss of the novel UDP-galactose transporter, Senju, causes abnormalities in immune organs. (A–C) Spontaneous melanization in the hemocoel and lymph glands in third-instar larvae of *senju*¹. *senju*¹ (B) and WT (C) lymph glands at high magnification. (Scale bars, 250 μ m.) (D–I) Lymph glands from WT (D, F, and H) and *senju*¹ (E, G, and I) late third-instar larvae carrying the *Dome*-MESO transgene (16) were stained with antibodies against the plasmatocyte marker, Nimrod (D and E); the undifferentiated cell marker, *Dome*-lacZ (F and G); and the lamellocyte marker, L1 (H and I) (green). Nuclei are stained with DAPI (blue). D'–I' show merged images. (Scale bars, 200 μ m.) The white dashed lines outline the lymph glands.




Fig. 2. Loss of *senju* induces hyperactivation of the innate immune response. (A) qRT-PCR analysis of *Drs* expression served as a readout for Toll signaling. *Drs* expression in challenged (+) and unchallenged (-) WT (CS) larvae [which was set at 1 (control)] and in the unchallenged mutant larvae *senju*¹, *senju*¹ *J4*, and *srp-Gal4* > *UAS-senjumyc* *senju*¹. (B and D) qRT-PCR analysis of other innate immunity genes, namely *Tep1* (used as a readout for the JAK/STAT pathway) (B) and *puc* (used as a readout for the JNK pathway) (D) in immune-challenged (+) and unchallenged (-) WT larvae (CS) and in the unchallenged mutant larvae, *senju*¹. The values in unchallenged WT were set at 1 (control). (C) *senju*¹;2xSTAT-GFP larvae also showed constitutive JAK/STAT pathway activation. (E) qRT-PCR analysis of *Dpt* (used as a readout for the Imd pathway) in *senju*¹ larvae in the absence of immune challenge. Larvae were challenged with *M. luteus* (A, B, and D). **P* < 0.05 and ***P* < 0.01 (Student *t* test).

to the unchallenged WT larvae (Fig. 2E), which suggests that the Imd signaling pathway is not activated in unchallenged *senju*¹.

From these results, we conclude that, with the exception of the Imd pathway, Senju-dependent glycosylation negatively regulates the key signaling pathways involved in innate immunity. We named the gene *senju*, which means “Buddha with a thousand hands manipulating tools to protect us,” because it seemed to protect against excessive activation of these signaling pathways.

Spz Is Activated in *senju*¹ in the Absence of Immune Challenge. We focused on the mechanisms underlying the hyperactivation of the Toll pathway in *senju*¹. The Golgi localization of Senju (29) (Fig. S4) suggests that Senju-dependent glycosylation of the membrane and/or secretory proteins of the Toll pathway regulate Toll activation (Fig. 3A). To identify which Toll pathway protein is activated in *senju*¹, we performed epistatic analysis with *senju*¹ and mutations in genes that encode extracellular components of the Toll pathway. Mutations in peptide glycan recognition proteins (PGRP-SA and GNB3), serine proteases (Grass and Psh), and the modulator protein ModSP did not prevent the induction of *Drs* expression in *senju*¹ (Fig. 3B). In addition, overexpression of the serine protease inhibitor *nec* did not affect the *Drs* mRNA levels in *senju*¹ (Fig. 3C). Spatzle-processing enzyme (SPE) is activated by ModSP-dependent and Psh-dependent pathways. When both signaling pathways were inhibited in *senju*¹ by mutations in *ModSP* and *psh*, the level of *Drs* transcription remained high (Fig. 3B). Because the *SPE* mutant has no null allele, we generated a new *SPE* mutant allele called *SPE*^{SK6} by using the Cas9-mediated gene targeting system (30). The *SPE*^{SK6} allele has an 8-bp deletion mutation (from nt 116 to nt 123)

in the coding region that results in the loss of the major protease domain (amino acids 135–400) of SPE (Fig. S5). *SPE*^{SK6} also did not block the up-regulation of *Drs* in *senju*¹. By contrast, the *senju*¹ and *spz*^{rm7} double mutant exhibited markedly reduced expression of *Drs* mRNA. This epistatic analysis placed Senju function at the level of Spz because Senju activated the Toll pathway independently of the cascade upstream of Spz.

We next examined whether Spz is activated in *senju*¹. Spz is mainly expressed in hemocytes and secreted to hemolymph in an inactive form designated as pro-Spz. When the immune system is stimulated, pro-Spz is cleaved by activated SPE to yield a short active form called Spz C106. Immunoblot analysis with an anti-Spz C106 antibody revealed markedly increased active Spz levels in the *senju*¹ hemolymph (Fig. 3D); thus, Spz is activated in *senju*¹ in the absence of immune challenge. These data demonstrated that Senju-dependent glycosylation prevents the aberrant activation of Spz and suppresses the Toll signaling pathway during the steady state.

Synthesis of Galactose-Containing N- and O-Glycans Is Impaired in *senju*¹. Because *senju* encodes a protein that is homologous to a NST, we investigated whether Senju is actually involved in glycosylation. First, we used a yeast cell-free system to identify the nucleotide sugar transported by Senju. We measured nucleotide sugar incorporation by microsomes extracted from yeasts that expressed *senju* or mock vector. The results clearly showed that the Senju protein selectively transports UDP-galactose, i.e., Senju is a UDP-galactose transporter (Fig. 4A).

Next, we examined the glycan structures that were altered in *senju*¹. To avoid feedback effects from the activated Toll signaling pathway, we compared the glycan profiles of the *dll/Dif* mutant and the *senju*¹ larvae in a *dll/Dif* mutant background by using a lectin array (31); thus, lymph gland lysates prepared from




Fig. 3. Spz is activated in *senju*¹ in the absence of immune challenge. (A) Schematic depiction of the extracellular Toll pathway. (B) Epistatic analysis of *senju*¹ and Toll activator mutants (*PGRP-SA*^{semi}, *GNBP3*^{hades}, *psh*¹, *ModSP*¹, *grass*^{Harrade}, *SPE*^{SK6}, and *spz*^{rm7}). *Drs* mRNA expression was measured by qRT-PCR, normalized, and expressed relative to that in *senju*¹ (which was set at 1). ***P* < 0.01 (Student *t* test). (C) Expression of *Drs* mRNA in *srp-Gal4* > *UAS-necmyc*; *senju*¹ larvae. (D) Immunoblot analysis of hemolymph from WT and *senju*¹ larvae using an anti-Spz C106 antibody. The image was taken in the same blotted membrane under the same conditions, and unnecessary lanes were removed.

control and *senju*¹ larvae were labeled with Cy3 and applied to the lectin array (which comprised 45 different lectins fixed on a glass slide). Because the coefficient of variation (CV) associated with this method is 10% (GlycoTechnica), changes in binding intensity of >20% (twice the CV) were considered significant. As shown in Fig. 4B and Dataset S1, five of the six lectins (RCA120, SNA, BPL, UEA-I, and MAL-I) that were less reactive with the *senju*¹ lysate than with the control lysate recognized *N*-linked and *O*-linked glycans that contained galactose. This reduction of galactose-containing glycans is consistent with the finding that Senju acts as a UDP-galactose transporter. Among the five lectins, BPL and RCA120 lectins provided higher signal intensities than the other three lectins (Dataset S1). By contrast, the lectins that were more reactive with the *senju*¹ lysates recognized mannose, GlcNAc, and GalNAc. These results indicate that some components of *N*-linked and *O*-linked glycans, which are distal to the galactose residue, are not synthesized in *senju*¹. Therefore, GlcNAc and GalNAc are exposed at the ends of these aberrant glycans, which may explain why the lectins recognizing GlcNAc and GalNAc were more reactive with *senju*¹ lysates.




Fig. 4. Senju, a UDP-galactose transporter, is required for the synthesis of galactose-containing glycans. (A) Transportation of various nucleotide sugar substrates by Senju. * $P < 0.05$ (Student *t* test). (B) Lectin microarray analysis of lymph glands from *dll/Dif* mutants (*J4*, control) and *senju*¹ with a *dll/Dif* mutant background (*J4, senju*¹). The binding of *senju*¹ lysates to less and more reactive lectins is shown relative to that of control fly lysates. The specificities of the lectins are shown. The galactose moieties are highlighted in red. (C) Synthesis of *N*-linked glycans on Myc-tagged Spz and SPE in *senju*¹. Immunoblot analysis using an anti-Spz C106 antibody (Upper) or an anti-Myc antibody (Lower), respectively. The genotypes of larvae used in this study were *srp-Gal4 > UAS-spz-myc* and *srp-Gal4 > UAS-spz-myc;senju*¹, or *srp-Gal4 > UAS-SPE-myc* and *srp-Gal4 > UAS-SPE-myc;senju*¹. The SPE image was taken in the same blotted membrane under the same conditions, and the left half was flipped horizontally. (D) *Drs* expression in WT flies after the transfer of native or heat-denatured *senju*¹ or WT hemolymph [which was set as 1 (control)]. * $P < 0.05$ (Student *t* test).

The next question was whether the glycosylation of components of the Toll signaling pathway is actually impaired in *senju*¹. We examined the glycosylation of Spz because, of all of the known extracellular components of the Toll pathway, Spz was the only protein that was required for the Toll hyperactivation in *senju*¹ (Fig. 3B). A Myc-tagged Spz protein was expressed using *srp-Gal4* in the immune organs of WT and *senju*¹ larvae. The protein was then immunopurified and subjected to immunoblot analysis with an anti-Myc antibody (Fig. 4C, Upper). Two bands were detected, both corresponding to expressed Spz. The difference in the molecular weights was due to heterogeneity of *N*-glycosylation: the proteins had the same molecular weight after treatment with PNGase, which specifically removes *N*-linked glycans from proteins. The higher-molecular-weight band (as indicated by the arrow in Fig. 4C, Upper), which is likely to represent Spz-bearing *N*-linked glycans with additional branching or extensions on galactose residues, was absent in *senju*¹. This result indicates that the *N*-linked glycans distal to galactose residues on Spz are not fully synthesized in *senju*¹ due to the low levels of UDP-galactose present in the Golgi lumen. The low-molecular-weight form of Spz (as indicated by the arrowhead in Fig. 4C, Upper) in *senju*¹ may also carry small but significant defects in glycosylation. Although defects in *N*-linked glycans could be detected by this electrophoretic analysis, it was hard to determine whether *O*-linked glycans were also impaired in *senju*¹ because *O*-linked glycans, apart from the glycosaminoglycan and mucin types, are generally smaller than *N*-linked glycans. We also investigated the glycosylation of SPE, which is not involved in Toll activation in *senju*¹ (Fig. 3B). Immunoblot analysis showed that the molecular weight of Myc-tagged SPE expressed in the immune organs of WT and *senju*¹ were the same and that treatment with PNGase F reduced the molecular weights of both proteins such that they were the same size. These results indicate that glycosylation of SPE is not impaired in *senju*¹ (Fig. 4C, Lower).

The data presented above suggested two possibilities: (i) that Senju-dependent glycosylation of Toll pathway proteins negatively regulates the Toll pathway and (ii) that the altered glycan structure in *senju*¹ is recognized as non-self, thereby leading to activation of the immune response. To distinguish between these two possibilities, we performed an experiment in which the hemolymph of WT and *senju*¹ larvae was transferred to WT flies. As expected, transfer of *senju*¹ hemolymph up-regulated Toll activation to a greater extent than transfer of WT hemolymph (Fig. 4D). If a Toll pathway protein is activated in *senju*¹, then heat-denatured *senju*¹ hemolymph would not up-regulate Toll activation to a greater extent than heat-denatured WT hemolymph. By contrast, if altered glycans activate the Toll pathway, heat-denatured *senju*¹ hemolymph (which contains altered glycans) would up-regulate the Toll pathway. The results clearly showed that the level of *Drs* mRNA in WT flies injected with heat-denatured *senju*¹ hemolymph was comparable with that in WT flies injected with heat-denatured WT hemolymph (Fig. 4D). These data suggest that Toll activation in *senju*¹ is likely caused by hyperactivation of a pathway protein rather than by the recognition of altered glycans as non-self.

Toll Activation Reduces Galactose-Containing Glycan Levels, Which Is Needed to Raise the Immune Response to an Adequate Level Following Infection. The data above suggested that galactose-containing glycans negatively regulate the Toll signaling pathway. This regulation is conserved at both the larval and adult stages because a few adult *senju* flies (escaper) exhibited significantly higher levels of *Drs* expression than adult control flies (Fig. S64). We next asked whether infection alters the amount of these glycan structures in adult flies, as infection experiments yielded more reliable results at the adult stage. To mimic pathogen infection, we first expressed the activated form of Toll, *Tl*^{10B}, in the fat body, an organ in which the Toll pathway is mainly activated after infection, and examined glycan expression in the hemolymph (which contains hemocytes and Spz) using a lectin array. The hemolymph of *Tl*^{10B}-expressing flies

showed almost no reactivity with BPL and RCA120 lectins (Fig. 5A). These results suggest that immune challenge causes degalactosylation of glycans. We further confirmed that infection by pathogens actually alters the amount of these glycan structures. Hemolymph from WT flies was collected 24 h after infection with *Bacillus subtilis* (*B. subtilis*). Lectin array analysis using BPL and RCA120 lectins showed that immune challenge reduced the level of reactivity with these lectins (Fig. 5B). Interestingly, the size of the reduction in reactivity with the BPL lectin after immune challenge was comparable with that observed in *senju*¹.

We next investigated whether the amounts of galactose-containing glycans affect the strength of the immune response to infection. The hemolymph of flies overexpressing Myc-tagged *senju* in immune organs (driven by *srp-Gal4*) showed markedly increased reactivity with BPL and RCA120 lectins, which recognize typical galactose residues, suggesting that *senju*-overexpressing flies have large amounts of galactose-containing glycans (Fig. 5C). Next, we examined whether *senju*-overexpressing flies exhibited reduced *Drs* mRNA expression after infection with gram-positive bacteria. Indeed, larvae and flies overexpressing *Senju* in immune organs (driven by *srp-Gal4*) showed 53% and 62% of the *Drs* mRNA levels observed in WT larvae and flies, respectively (Fig. 5D). Finally, we used the ubiquitously expressed driver, *da-Gal4*, to test susceptibility to microbial infection in *senju*-overexpressing flies. Following immune challenge with *B. subtilis*, the survival rate of *senju*-overexpressing flies was lower (61.5% at 45 h after infection) than that of WT flies (87.1%) (Fig. 5E). A similar result was obtained when we used *srp-Gal4* to overexpress *Senju* in immune organs (Fig. 5F). This reduced resistance of *senju*-overexpressing flies to *B. subtilis* infection was consistent with the low-level induction of *Drs* mRNA. Taken together, we conclude that high levels of galactose-containing glycans reduce the strength of the immune response following infection.

Discussion

Proper regulation of immune responses is critical for health. Inappropriate activation of inflammatory responses or lack of immune signaling lead to serious conditions such as inflammatory diseases or immunodeficiency, respectively. Recent studies reveal that innate immunity is regulated by multiple factors, including sumoylation and the retromer complex, which fine tune immune activity (32, 33). The present study clearly showed that glycosylation plays an important role in maintaining innate immune homeostasis and activation of immune responses.

Several studies show that pathogen glycans are involved in pathogen recognition and the interactions between host molecules and microbes (34, 35); however, the mechanisms by which host glycans regulate innate immune signaling pathways in vivo remain to be identified. The present study provides in vivo evidence for the essential role of host glycosylation in innate immune quiescence. *Drosophila* immunity is controlled by various signaling pathways such as Toll, Imd, JNK and JAK/STAT pathways. In *senju* mutants, Toll, JNK, and JAK/STAT pathways were activated in the absence of infection. Because these pathways can activate each other by complex cross-talk, it is difficult to determine whether only the Toll pathway or all or some of the other pathways are also directly activated in *senju*¹.

Our epistatic analysis suggested that the constitutive activation of the Toll pathway in *senju*¹ depends on Spz. The precursor form of Spz is N-glycosylated, and the Spz molecules that are expressed in *senju*¹ exhibited impaired glycan synthesis (Fig. 4C). By contrast, no glycan defects were observed in the SPE expressed in *senju*¹ (Fig. 4C). SPE is not necessary for Toll pathway activation in *senju*¹ (Fig. 3B); thus, Spz is a candidate protein whose inadequate glycosylation may be responsible for the hyperactivation of the Toll pathway in *senju*¹. It remains possible that the *Senju*-dependent glycan regulates an unknown pathway that can activate Spz.

Genetic remodeling of protein glycosylation in mice reveals that glycans play important roles in autoimmune disease and inflammation (36). Conversely, infection and inflammation lead to changes in host glycan structure (37). Although it is well known that pathogens express enzymes that directly alter host glycans and thereby facilitate their life cycle (e.g., *Haemophilus influenzae*), it is unclear whether glycan changes that are achieved by the host cellular machinery (e.g., by regulating glycosyltransferase or other pathways) are beneficial for host defense. Our results show that host-driven glycan changes in response to Toll activation may be an efficient mechanism by which the host combats microbes. As mentioned above, galactose-containing glycan is a negative regulator of Toll signaling. When the Toll pathway is activated by infection, the galactose-containing glycan levels decrease (Fig. 5B). This effect is independent of pathogen-derived enzymes because these glycan changes were observed in *Tl*^{10B}-expressing flies that had not been challenged with pathogen (Fig. 5A). The degalactosylation may result in up-regulation of the Toll signaling pathway because the analysis of *senju* mutants showed that deletion of galactose residues increased Toll signaling. These glycan changes induced by Toll activation may contribute to the rapid




Fig. 5. Toll activation results in reduced levels of galactose-containing glycans in the hemolymph, which raises the immune response to an adequate level. (A) BPL and RCA120 lectin reactivity of the control (*lsp2-Gal4*, -) and Toll-activated (*lsp2-Gal4* > *UAS-Tl*^{10B}, *Tl*^{10B}) hemolymph. (B) BPL and RCA120 lectin reactivity of immune-challenged (with *B. subtilis*) (+), unchallenged (-) WT, and unchallenged (-) *senju*¹ hemolymph. (C) BPL and RCA120 lectin reactivity of *senju*-overexpressing (*srp-Gal4* > *UAS-senjumyc*) (+) and control (*srp-Gal4*, -) hemolymph. (D) *Drs* expression in immune-challenged (with *B. subtilis*) larvae and adult flies. (+) indicates *senju*-overexpressing strains and (-) indicates control *srp-Gal4* strains (set at 1). **P* < 0.05 (Student *t* test). (E) Survival of *senju*-overexpressing (*daGal4* > *UAS-senjumyc*, *Da* > *senju*) and control (*daGal4* >, *Da*) flies after immune challenge with *B. subtilis* (+) or no challenge (-).

elimination of pathogens in the acute phase in cooperation with the increased expression of *spz*, *Tl*, and *SPE*. *Senju*-overexpressing flies, which have large amounts of galactose-containing glycan (Fig. 5C), showed reduced *Drs* expression and viability after infection (Fig. 5D and E and Fig. S6B), which suggests that the reduction in the levels of galactose-containing glycan is important for generating adequate immune responses to infections. Taken together, the results of the present study indicate the presence of a novel mechanism that regulates the immune response through changes in glycan structure.

Degalactosylation is thought to be caused by two possible mechanisms. One is activation of the degradation of galactose-containing glycans associated with Toll activation. Another mechanism is suppression of synthesis of galactose-containing glycans. Recent reports showed that treatment with proinflammatory cytokines (IL-1 and TNF α) affects the expression of glycosyltransferases and leads to glycan changes in mammals (38, 39). Therefore, the activation of Toll signaling by infection may also involve regulation of the activity of as-yet-unidentified galactosyltransferases and/or enzymes that are required for UDP-galactose biosynthesis, although the level of *senju* mRNA in the *Tl*^{10B}-expressing flies was unchanged (Fig. S7). Further studies are needed to fully understand the mechanisms underlying the changes in glycan structure that occur in response to Toll pathway activation.

In summary, we identified a novel mechanism that regulates innate immune quiescence and activation via changes in glycosylation status during steady state and infection, respectively.

- Lemaitre B, Hoffmann J (2007) The host defense of *Drosophila melanogaster*. *Annu Rev Immunol* 25:697–743.
- Ferrandon D, Imler JL, Hetru C, Hoffmann JA (2007) The *Drosophila* systemic immune response: Sensing and signalling during bacterial and fungal infections. *Nat Rev Immunol* 7(11):862–874.
- Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. *Nat Immunol* 11(5):373–384.
- Häcker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: The sweet side of development. *Nat Rev Mol Cell Biol* 6(7):530–541.
- Yamamoto-Hino M, Okano H, Kanie O, Goto S (2012) Structure, function and formation of glycans in *Drosophila*. *Glycans: Biochemistry, Characterization and Applications*, ed Mora Montes HM (Nova Science Publishers New York).
- Liu L, Xu YX, Hirschberg CB (2010) The role of nucleotide sugar transporters in development of eukaryotes. *Semin Cell Dev Biol* 21(6):600–608.
- Selva EM, et al. (2001) Dual role of the fringe connection gene in both heparan sulphate and fringe-dependent signalling events. *Nat Cell Biol* 3(9):809–815.
- Goto S, et al. (2001) UDP-sugar transporter implicated in glycosylation and processing of Notch. *Nat Cell Biol* 3(9):816–822.
- Ishikawa HO, et al. (2005) Notch deficiency implicated in the pathogenesis of congenital disorder of glycosylation IIc. *Proc Natl Acad Sci USA* 102(51):18532–18537.
- Ishikawa HO, et al. (2010) Two pathways for importing GDP-fucose into the endoplasmic reticulum lumen function redundantly in the O-fucosylation of Notch in *Drosophila*. *J Biol Chem* 285(6):4122–4129.
- Lühn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D (2001) The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. *Nat Genet* 28(1):69–72.
- Lübke T, et al. (2001) Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. *Nat Genet* 28(1):73–76.
- Crozatier M, Meister M (2007) *Drosophila* haematopoiesis. *Cell Microbiol* 9(5):1117–1126.
- Kurucz E, et al. (2007) Nimrod, a putative phagocytosis receptor with EGF repeats in *Drosophila* plasmatocytes. *Curr Biol* 17(7):649–654.
- Kurucz E, et al. (2007) Definition of *Drosophila* hemocyte subsets by cell-type specific antigens. *Acta Biol Hung* 58(Suppl):95–111.
- Krzemień J, et al. (2007) Control of blood cell homeostasis in *Drosophila* larvae by the posterior signalling centre. *Nature* 446(7133):325–328.
- Qiu P, Pan PC, Govind S (1998) A role for the *Drosophila* Toll/Cactus pathway in larval hematopoiesis. *Development* 125(10):1909–1920.
- Luo H, Hanratty WP, Dearolf CR (1995) An amino acid substitution in the *Drosophila* hopTum-I Jak kinase causes leukemia-like hematopoietic defects. *EMBO J* 14(7):1412–1420.
- Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N (1995) Activation of a *Drosophila* Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. *EMBO J* 14(12):2857–2865.
- Hetru C, Hoffmann JA (2009) NF-kappaB in the immune response of *Drosophila*. *Cold Spring Harb Perspect Biol* 1(6):a000232.
- Agaisse H, Perrimon N (2004) The roles of JAK/STAT signaling in *Drosophila* immune responses. *Immunol Rev* 198:72–82.
- Lagueux M, Perrodou E, Levashina EA, Capovilla M, Hoffmann JA (2000) Constitutive expression of a complement-like protein in toll and JAK gain-of-function mutants of *Drosophila*. *Proc Natl Acad Sci USA* 97(21):11427–11432.
- Bach EA, et al. (2007) GFP reporters detect the activation of the *Drosophila* JAK/STAT pathway in vivo. *Gene Expr Patterns* 7(3):323–331.
- Sluss HK, et al. (1996) A JNK signal transduction pathway that mediates morphogenesis and an immune response in *Drosophila*. *Genes Dev* 10(21):2745–2758.
- Boutros M, Agaisse H, Perrimon N (2002) Sequential activation of signaling pathways during innate immune responses in *Drosophila*. *Dev Cell* 3(5):711–722.
- Delaney JR, et al. (2006) Cooperative control of *Drosophila* immune responses by the JNK and NF-kappaB signaling pathways. *EMBO J* 25(13):3068–3077.
- Martin-Blanco E, et al. (1998) Puckered encodes a phosphatase that mediates a feedback loop regulating JNK activity during dorsal closure in *Drosophila*. *Genes Dev* 12(4):557–570.
- Lemaitre B, et al. (1995) A recessive mutation, immune deficiency (*imd*), defines two distinct control pathways in the *Drosophila* host defense. *Proc Natl Acad Sci USA* 92(21):9465–9469.
- Yamamoto-Hino M, et al. (2012) Cisterna-specific localization of glycosylation-related proteins to the Golgi apparatus. *Cell Struct Funct* 37(1):55–63.
- Kondo S, Ueda R (2013) Highly improved gene targeting by germline-specific Cas9 expression in *Drosophila*. *Genetics* 195(3):715–721.
- Hirabayashi J, Yamada M, Kuno A, Tatenno H (2013) Lectin microarrays: Concept, principle and applications. *Chem Soc Rev* 42(10):4443–4458.
- Anjum SG, et al. (2013) Regulation of Toll signaling and inflammation by β -arrestin and the SUMO protease Ulp1. *Genetics* 195(4):1307–1317.
- Zhou B, et al. (2014) Retromer promotes immune quiescence by suppressing Spätzle-Toll pathway in *Drosophila*. *J Cell Physiol* 229(4):512–520.
- Vasta GR (2009) Roles of galectins in infection. *Nat Rev Microbiol* 7(6):424–438.
- Royet J, Gupta D, Dziarski R (2011) Peptidoglycan recognition proteins: Modulators of the microbiome and inflammation. *Nat Rev Immunol* 11(12):837–851.
- Orr SL, et al. (2013) A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. *Glycobiology* 23(3):363–380.
- Kreisman LS, Cobb BA (2012) Infection, inflammation and host carbohydrates: A Glyco-Evasion Hypothesis. *Glycobiology* 22(8):1019–1030.
- Higai K, Miyazaki N, Azuma Y, Matsumoto K (2006) Interleukin-1 β induces sialyl Lewis X on hepatocellular carcinoma HuH-7 cells via enhanced expression of ST3Gal IV and FUT VI gene. *FEBS Lett* 580(26):6069–6075.
- Colomb F, et al. (2012) TNF regulates sialyl-Lewisx and 6-sulfo-sialyl-Lewisx expression in human lung through up-regulation of ST3Gal4 transcript isoform BX. *Biochimie* 94(9):2045–2053.

Materials and Methods

Generation of *senju* KO Flies. *senju* KO flies were generated using ends-out technology. A targeting vector was designed to replace the entire *senju* gene with the *white* gene. See *SI Materials and Methods* for a detailed description.

Quantitative RT-PCR. Real-time PCR was performed by using a 7500HT Fast Real-Time PCR system (Applied Biosystems). The amounts of amplified transcript were normalized against an internal control (*ribosomal protein 32*). See *SI Materials and Methods* for a detailed description. The primers used are listed in *Table S1*.

Lectin Array. Extracted proteins (1 μ g) from lymph glands or hemolymph were labeled with Cy3 Monoreactive Dye (GE Healthcare) and subjected to glycan profiling analyses using their LecChip lectin array chips and an evanescent-field fluorescence scanner (Glycostation Reader 1200; SC-Profler; Glycotecnica Ltd.; www.glycotecnica.com). The net signal intensity values from three spots were then averaged. See *SI Materials and Methods* for a detailed description.

Statistical Analysis. Statistical analysis was performed by the Student t test using Microsoft Excel.

ACKNOWLEDGMENTS. We thank Ms. Wakae Awano for excellent technical support and peoples and stock centers listed in *Table S2* for providing fly strains. This work was supported by grants-in-aid for scientific research from Ministry of Education, Culture, Sports, Science and Technology, and Japan Society for the Promotion of Science and a grant from The Sumitomo Foundation.